bavdegalutamide
bavdegalutamide: developed by 1 company · 2 clinical trials tracked.
bavdegalutamide evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could bavdegalutamide → ARVN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| ARVINAS, INC. (ARVN) Prostate Cancer Metastatic | Phase 1 |
Clinical Trials (2)
A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination With Abiraterone in Patients With Metastatic Prostate Cancer
Primary endpoint: Safety Lead-in: Number of Participants Experiencing Dose Limiting Toxicities (DLTs)
A Phase 1/2, Open-label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Primary endpoint: Part A: Incidence of Dose Limiting Toxicities of ARV-110
Frequently asked questions
Who is developing bavdegalutamide?
bavdegalutamide is being developed by ARVINAS, INC..
How many clinical trials involve bavdegalutamide?
BioSniper tracks 2 clinical trials involving bavdegalutamide.